Document is current

Article History

Received: 23 October 2025

Accepted: 22 December 2025

First Online: 23 February 2026

Declarations

:

: The study was conducted in accordance with the Declaration of Helsinki and the International Council on Harmonisation Guidelines for Good Clinical Practice. The study protocol was approved by each study site’s Institutional Review Board/Independent Ethics Committee prior to initiation.

: All patients provided written informed consent prior to study participation.

: Jack R. Andrews has participated in advisory boards for Blue Earth Diagnostics Ltd., Bayer, and Novartis. Benjamin A. Gartrell has received research funding from Pfizer and has served on advisory boards/speaker’s bureau for Bayer, Eisai, Johnson & Johnson, Novartis, Pfizer, Astellas, Blue Earth Diagnostics, Seagen, Aveo and BMS. Phillip H. Kuo has received research grants from Blue Earth Diagnostics and General Electric Healthcare. He is a consultant and/or speaker for Attralus, Bayer, Blue Earth Diagnostics, dGenThera, Eli Lilly, Fusion Pharma, General Electric Healthcare, Global Medical Solutions, Invicro/Perceptive, Life Molecular Imaging, Merck, Navidea, Novartis, Radionetics, Telix Pharmaceuticals, and United Imaging, and participates on a scientific advisory board for dGenThera. Andrei S. Purysko has received a research grant for the present study, and consulting fees, from Blue Earth Diagnostics Ltd., and has received research grants from Lantheus Diagnostic and Therapeutic Innovations and Siemens Healthineers. James Sykes and Ross Penny are employees of Blue Earth Diagnostics Ltd. Phillip Davis was an employee of Blue Earth Diagnostics Inc. during the time this study was conducted. Brian T. Helfand reports research funding from Blue Earth Diagnostics for the present study. All other authors have no relevant disclosures.